However, despite this limitation, the spatial patterns of biological effects observed from PSMA-targeted radiopharmaceutical therapy across three distinct prostate cancer tissues (PC1, PC2, and PC3) were consistent with prostate cancer cell fractions as depicted in Figure S3B. Here, FOLH1 is linked to prostate carcinoma.